EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical and Genomic Features and Prognostic Biomarkers of Oligometastatic Nonsmall Cell Lung Cancer

Rebecca A Deek, Jongmyung Kim, Ritesh Kumar, Benjamin Medina, John Langenfeld, Ioannis Kontopidis, Richard Lazzaro, Ke Nie, Lara Hathout, Ozan Guler, Cem Onal, Eshan Patel und 3 weitere

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2025.07.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Rebecca A Deek und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, University of Pittsburgh, Pittsburg, PA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, US Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Treatment of metastatic disease is rapidly evolving with local therapies increasingly being used in patients with oligometastasis. Better personalization is needed to appropriate select patients for these interventions. We attempted to better understand clinical features and genomic features of oligometastatic nonsmall cell lung cancer (NSCLC). MATERIALS AND METHODS: Patients with metastatic NSCLC were included and underwent next generation sequencing. Patients were defined as having either oligometastatic (≤5 lesions) or polymetastatic (≥ 6 lesions) disease. Median overall survival (mOS) was computed using the Kaplan Meier method and multivariable Cox regression (MVA) analyses performed. DAVID and PANTHER analysis identified pathways differing between oligo and polymetastasis. RESULTS: A total of 406 patients were included. Oligometastasis was associated with improved mOS compared to polymetastasis (25.9 months vs. 18.7 months, P = .02) and remained so on MVA (HR 0.60, P < .001). Genetic features differed between oligometastatic and polymetastatic NSCLC. Oligometastatic patients had higher incidence of alterations in PI3K pathway genes (24.3% vs. 14.7%, P = .03) and LRPB1 (7.8% vs. 2.5%, P = .03). while polymetastatic patients had higher incidence of mutations in EGFR (33.1% vs. 21.4%, P = .01) and ALK (8.6% vs. 3.3%, P = .03). On DAVID analysis, pathways important in motility and epithelial mesenchymal transition, including WNT and TGFB, were enriched in patients with polymetastasis. CONCLUSIONS: Oligometastasis is associated with improved prognosis. The underlying genetic composition differs between oligo and polymetastasis and might aid in better defining metastatic disease with loco-regional behaviors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkers, TumorHumansMaleFemalePrognosisMiddle AgedAgedGenomicsMutationNeoplasm MetastasisHigh-Throughput Nucleotide SequencingSurvival RateFollow-Up StudiesAdult

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Biostatistics, University of Pittsburgh, Pittsburg, PA.
  • Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ.
  • Department of Surgery, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ.
  • Department of Radiation Oncology, Baskent University, Ankara, Turkey.
  • Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ.
  • Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ. Electronic address: matthewdeek@gmail.com.

Förderung

  • NCI NIH HHS
  • US Department of Defense

Zitieren

APA

Deek, R. A., Kim, J., Kumar, R., Medina, B., Langenfeld, J., Kontopidis, I., Lazzaro, R., Nie, K., Hathout, L., Guler, O., Onal, C., Patel, E., Haigentz, M., Jabbour, S. K., & Deek, M. P. (2025). Clinical and Genomic Features and Prognostic Biomarkers of Oligometastatic Nonsmall Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.07.010

Vancouver

Deek RA, Kim J, Kumar R, Medina B, Langenfeld J, Kontopidis I, et al. Clinical and Genomic Features and Prognostic Biomarkers of Oligometastatic Nonsmall Cell Lung Cancer. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.07.010

BibTeX
@article{Deek2025,
  author = {Deek, Rebecca A and Kim, Jongmyung and Kumar, Ritesh and Medina, Benjamin and Langenfeld, John and Kontopidis, Ioannis and Lazzaro, Richard and Nie, Ke and Hathout, Lara and Guler, Ozan and Onal, Cem and Patel, Eshan and Haigentz, Missak and Jabbour, Salma K and Deek, Matthew P},
  title = {Clinical and Genomic Features and Prognostic Biomarkers of Oligometastatic Nonsmall Cell Lung Cancer},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2025.07.010}
}
Kostenlos starten →